In our exclusive interview, Dr. Riess discussed the excitement surrounding KRAS G12C inhibitors in NSCLC, preliminary efficacy and safety data with AMG 510, and additional research regarding co-mutations and combinations that could lead to further refinement of the potential role of the agent in the landscape.

S3 Ep24: Talking KRAS-Targeted Therapy in NSCLC With Dr. Riess

<p>In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.</p>

Science

Health & Fitness

In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.

Share S3 Ep24: Talking KRAS-Targeted Therapy in NSCLC With Dr. Riess

Sign up to save your podcasts

S3 Ep24: Talking KRAS-Targeted Therapy in NSCLC With Dr. Riess

S3 Ep24: Talking KRAS-Targeted Therapy in NSCLC With Dr. Riess

More shows like OncLive® On Air

Left, Right & Center

The Ben Shapiro Show

NEJM This Week

Nature Podcast

Research To Practice | Oncology Videos

ASCO Daily News

Audio Journal of Oncology Podcast

OncoPharm

ASCO Guidelines

The Uromigos

Simple English News Daily

Oncology Today with Dr Neil Love

People I (Mostly) Admire

Oncology Brothers: Practice-Changing Cancer Discussions

English Learning Podcast